Valuation Clinuvel Pharmaceuticals Limited Deutsche Boerse AG
Stocks
UR9
AU000000CUV3
Pharmaceuticals
|
Market Closed -
Deutsche Boerse AG
20:41:16 03/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 5.300 EUR | 0.00% |
|
-15.06% | -24.29% |
| 08-28 | Morgans Financial Downgrades Clinuvel Pharmaceuticals to Hold from Speculative Buy; Price Target is AU$10 | MT |
| 08-27 | Clinuvel Pharmaceuticals Limited, 2026 Earnings Call, Aug 27, 2026 |
Company Valuation: Clinuvel Pharmaceuticals Limited
Data adjusted to current consolidation scope
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 733.7 | 883.5 | 769.8 | 520.3 | 518.4 | 416.5 | - | - |
| Change | - | 20.4% | -12.87% | -32.41% | -0.36% | -19.65% | - | - |
| Enterprise Value (EV) 1 | 612.2 | 726.6 | 585.9 | 296.2 | 518.4 | 132.6 | 99.23 | 59.78 |
| Change | - | 18.69% | -19.37% | -49.45% | 75.03% | -74.41% | -25.19% | -39.76% |
| P/E | 36.8x | 30.3x | 22x | 14.5x | 15.4x | 11.6x | 11x | 7.68x |
| PBR | 5.84x | 5.37x | 3.79x | 2.17x | - | 1.36x | 1.23x | 1.05x |
| PEG | - | 0.6x | 1.2x | 5.06x | -2.21x | 1.79x | 1.97x | 0.2x |
| Capitalization / Revenue | 11.2x | 11.3x | 8.73x | 5.48x | 5.51x | 4.39x | 4.04x | 3.03x |
| EV / Revenue | 9.32x | 9.28x | 6.64x | 3.12x | 5.51x | 1.4x | 0.96x | 0.44x |
| EV / EBITDA | 16.4x | 19.5x | 12x | 6.84x | 13.6x | 3.5x | 2.37x | 0.97x |
| EV / EBIT | 16.7x | 20x | 12.3x | 7.03x | 13.9x | 3.6x | 2.44x | 0.99x |
| EV / FCF | 15.5x | 20.2x | 18.6x | 7.26x | - | 3.62x | 2.45x | 1.03x |
| FCF Yield | 6.44% | 4.94% | 5.37% | 13.8% | - | 27.7% | 40.8% | 97.1% |
| Dividend per Share 2 | 0.04 | 0.05 | 0.05 | 0.05 | - | 0.0547 | 0.065 | 0.0913 |
| Rate of return | 0.27% | 0.28% | 0.33% | 0.48% | - | 0.66% | 0.79% | 1.11% |
| EPS 2 | 0.403 | 0.591 | 0.698 | 0.718 | 0.668 | 0.7112 | 0.7508 | 1.076 |
| Distribution rate | 9.93% | 8.46% | 7.16% | 6.96% | - | 7.69% | 8.66% | 8.49% |
| Net sales 1 | 65.72 | 78.32 | 88.18 | 95.02 | 94.02 | 94.86 | 103 | 137.3 |
| EBITDA 1 | 37.44 | 37.2 | 48.95 | 43.3 | 38.2 | 37.94 | 41.81 | 61.94 |
| EBIT 1 | 36.68 | 36.41 | 47.81 | 42.12 | 37.21 | 36.85 | 40.62 | 60.47 |
| Net income 1 | 20.88 | 30.6 | 35.64 | 36.17 | 33.92 | 36.02 | 38.1 | 54.47 |
| Net Debt 1 | -121.5 | -156.8 | -183.9 | -224.1 | - | -283.9 | -317.3 | -356.8 |
| Reference price 2 | 14.850 | 17.880 | 15.370 | 10.380 | 10.280 | 8.260 | 8.260 | 8.260 |
| Nbr of stocks (in thousands) | 49,410 | 49,410 | 50,083 | 50,124 | 50,428 | 50,428 | - | - |
| Announcement Date | 30/08/22 | 29/08/23 | 28/08/24 | 27/08/25 | 27/08/26 | - | - | - |
1AUD in Million2AUD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 19.73x | 4.62x | 10.89x | 0.46% | 85.08B | |
| -17.67x | 26.98x | -17.48x | -.--% | 60.21B | |
| 20.41x | 4.36x | 13.47x | 2.41% | 59.71B | |
| 36.57x | 12.46x | 23.89x | -.--% | 51.1B | |
| 22.01x | 4.87x | 13.87x | 0.66% | 48.73B | |
| 39.56x | 3.62x | 13.81x | -.--% | 32.9B | |
| 57.49x | 3.68x | 28.54x | -.--% | 26.11B | |
| 67.86x | 7.21x | 43.87x | -.--% | 22.6B | |
| 23.85x | 5.12x | 13.34x | -.--% | 16.42B | |
| Average | 29.98x | 8.10x | 16.02x | 0.39% | 44.76B | |
| Weighted average by Cap. | 23.59x | 8.97x | 12.37x | 0.53% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CUV Stock
- UR9 Stock
- Valuation Clinuvel Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
